Drug Safety

, Volume 22, Issue 3, pp 169–177 | Cite as

Assessing the Safety of Drugs in Pregnancy

The Role of Prospective Cohort Studies
Leading Article

Abstract

Since, for obvious reasons, systematic testing of the teratogenic properties of drugs in humans is not possible in the premarketing phase, the epidemiological approaches to postmarketing risk evaluation are of major importance. Cohort studies, with their prospective exposure assessment, their ability to study even exposure to drugs not commonly used in pregnancy, and their ability to monitor both adverse and beneficial fetal outcomes, seem to be the most promising study type from a methodological viewpoint. Although there are numerous cohort studies on the harmful effects of drug use in pregnant women, only a few have been able to demonstrate a risk in terms of an increase in the prevalence of malformations. Most studies with significant findings were those investigating the risk potential of one group of drugs, the anticonvulsants. The lack of cohort studies showing a risk for drug use in pregnancy, however, is not necessarily indicative of some methodological deficiency. Rather, it may suggest that, for the majority of drugs, their use in pregnancy is not associated with an increased risk of congenital malformations.

Keywords

Thalidomide Prospective Cohort Study Congenital Malformation Isotretinoin Neural Tube Defect 

References

  1. 1.
    Gregg NM. Congenital cataract following German measles in mother. T Ophthal Soc Aust 1941; 3: 35–46Google Scholar
  2. 2.
    Lenz W. Kindliche Miβbildungen nach Medikament während der Gravidität? Dtsch Med Wochenschr 1961; 86: 2555–6Google Scholar
  3. 3.
    Lenz W, editor. A Symposium on embryopathic activity of drugs. London: Churchill, 1965Google Scholar
  4. 4.
    Koren G, Pastuszak A, Ito S. Drugs in pregnancy. New Engl J Med 1998; 338 (16): 1128–37PubMedCrossRefGoogle Scholar
  5. 5.
    Magee LA, Schick B, Donnenfeld AE, et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynaecol 1996; 174 (3): 823–8CrossRefGoogle Scholar
  6. 6.
    Czeizel AE, Intôdy Z,Modell B.What proportion of congenital abnormalities can be prevented? BMJ 1993; 306: 499–503PubMedCrossRefGoogle Scholar
  7. 7.
    Queiβer-Luft A, Eggers I, Stolz G, et al. Serial examination of 20 248 newborn fetuses and infants: correlations between drug exposure and major malformations. Am J Med Genet 1996; 63: 268–76CrossRefGoogle Scholar
  8. 8.
    Rösch C, Zeidler M, Steinbicker V. Erfassung von Fehlbildungen und Anomalien im egierungsbezirk Magdeburg. Ärzteblatt Sachsen-Anhalt 1996; 7 (10): 24–647Google Scholar
  9. 9.
    EUROCAT Working Group. EUROCAT Report 7: 15 years of surveillance of congenital anomalies in Europe 1980–1994. Brussels: Scientific Institute of Public Health-Louis Pasteur, 1997Google Scholar
  10. 10.
    Khoury MJ, Holtzman NA. On the ability of birth defects monitoring to detect new teratogens. Am J Epidemiol 1987; 126: 136–43PubMedGoogle Scholar
  11. 11.
    Mackenzie SG, Lipoman A. An investigation of report bias in a case-control study of pregnancy outcome. Am J Epidemiol 1989; 129 (1): 65–75PubMedGoogle Scholar
  12. 12.
    Werler MM, Pober BR, Nelson K, et al. Reporting accuracy amongmothers ofmalformed and nonmalformed infants.Am J Epidemiol 1989; 129 (2): 415–21PubMedGoogle Scholar
  13. 13.
    Feldman Y, Koren G, Mattice D, et al. Determinants of recall and recall bias in studying drug and chemical exposure in pregnancy. Teratology 1989; 40: 37–45PubMedCrossRefGoogle Scholar
  14. 14.
    Klemetti A, Saxen L. Prospective versus retrospective approach in the search for environmental causes of malformations. Am J Pub Health 1967; 57: 2071–5Google Scholar
  15. 15.
    Mitchell AA, Cottler LB, Shapiro S. Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 1986; 123 (4): 670–6PubMedGoogle Scholar
  16. 16.
    Mitchell AA. Special considerations in studies of drug-induced birth defects. In: Strom BL, editor. Pharmacoepidemiology. 2nd ed. New York: John Wiley, 1994: 595–608Google Scholar
  17. 17.
    Källén B. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Br J Obstet Gynaecol 1998; 105: 877–81PubMedCrossRefGoogle Scholar
  18. 18.
    Inman W, Pearce G, Wilton L. Safety of fluconazole in the treatment of vaginal candidiasis: a prescription-event monitoring study, with special reference to the outcome of pregnancy. Eur J Clin Pharmacol 1994; 46: 115–8PubMedCrossRefGoogle Scholar
  19. 19.
    Wilton LV, Pearce GL, Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br J Clin Pharmacol 1996; 41: 277–84PubMedCrossRefGoogle Scholar
  20. 20.
    Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia 1996; 37 Suppl. 6: S34–44PubMedCrossRefGoogle Scholar
  21. 21.
    Lawson DH. Postmarketing surveillance versus clinical trials: which benefits the patient? Cardiology 1994; 85 Suppl. 1: 18–23PubMedGoogle Scholar
  22. 22.
    Manson JM, Freyssinges C, Ducrocq MB, et al. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol 1996; 10 (6): 439–46PubMedCrossRefGoogle Scholar
  23. 23.
    Weatherall JAC, Greenberg G. Maternal drug usage and congenital malformations. Contr Epidemiol Biostatist 1979, 1: 71–7Google Scholar
  24. 24.
    Dravet C, Julian C, Legras C, et al. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 1992; 42 (4) Suppl. 5: 75–82Google Scholar
  25. 25.
    Gladstone DJ, BologaM,MaguireC, et al. Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Reprod Toxicol 1992; 6 (3): 257–61PubMedCrossRefGoogle Scholar
  26. 26.
    Lindhout D, Meinardi H, Meijer JW, et al. Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology 1992; 42 (4) Suppl. 5: 94–110Google Scholar
  27. 27.
    Waters CH, Belai Y, Gott PS, et al. Outcomes of pregnancy associatedwith antiepileptic drugs. Arch Neurol 1994; 51 (3): 250–3PubMedCrossRefGoogle Scholar
  28. 28.
    Koller S. Risikofaktoren der Schwangerschaft: Auswertung von 7870 Schwangerschaften der prospektiven Untersuchungsreihe ‘Schwangerschaftsverlauf und Kindesentwicklung’ der Deutschen Forschungsgemeinschaft. Berlin: Springer-Verlag, 1983CrossRefGoogle Scholar
  29. 29.
    Briggs GG, Freeman RK, Sumner JY. Drugs in pregnancy and lactation. 5th ed. Baltimore: Williams and Wilkins, 1998Google Scholar
  30. 30.
    Irl C, Kipferler P, Hasford J. Drug use assessment and risk evaluation in pregnancy: the PEGASUS-project. Pharmacoepidemiol Drug Saf 1997; 6 Suppl. 3: 37–42CrossRefGoogle Scholar
  31. 31.
    Irl C, Hasford J, the PEGASUS-Study Group. The PEGASUS-project: a prospective cohort study for the investigation of drug use in pregnancy. Int J Clin Pharmacology Ther 1997; 35: 572–6Google Scholar
  32. 32.
    Magee LA, Inocencion G, Kamboj L, et al. Safety of first trimester exposure to histamine H2 blockers: a prospective cohort study. Dig Dis Sci 1996; 41 (6): 1145–9PubMedCrossRefGoogle Scholar
  33. 33.
    Shapiro L, Pastuszak A, Curto G, et al. Safety of first-trimester exposure to topical tretinoin: prospective cohort study. Lancet 1997; 350: 1143–4PubMedCrossRefGoogle Scholar
  34. 34.
    Diav-Citrin O, Park Y-H, Veerasuntharam G, et al. The safety of Mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998; 114: 23–8PubMedCrossRefGoogle Scholar
  35. 35.
    Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. J Am Med Assoc 1998; 279 (8): 609–10CrossRefGoogle Scholar
  36. 36.
    Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 1998; 42 (6): 1336–9PubMedCentralPubMedGoogle Scholar
  37. 37.
    Shuhaiber S, Pastuzak A, Schick B, et al. Pregnancy outcome following first trimester exposure to sumatriptan. Neurology 1998; 51 (2): 581–3PubMedCrossRefGoogle Scholar
  38. 38.
    Lalkin A, Loebstein R, Addis A, et al. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol 1998; 179: 727–30PubMedCrossRefGoogle Scholar
  39. 39.
    Andrews EB, Yankaskas BC, Cordero JF, et al. The acyclovir in pregnancy registry: six years’ experience. Obstet Gynecol 1992; 79: 7–13PubMedGoogle Scholar
  40. 40.
    Bonati M, Bortolus B, Marchetti F, et al. Drug use in pregnancy: an overview of epidemiological (drug utilization) studies. Clin Pharmacol 1990; 38: 325–8Google Scholar
  41. 41.
    Reimann IR, Karpinsky C, Hoffmann A. Epidemiological data on drug use during pregnancy in Thuringia, East Germany, 1993. Int J Clin Pharmacol Ther 1996; 34: 80–3PubMedGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Institute for Medical Informatics, Biometry and EpidemiologyUniversity of MunichMunichGermany

Personalised recommendations